BRL-37344

BRL-37344
Clinical data
Trade names	BRL-37344
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name 2-[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}propyl]phenoxy}acetic acid;
CAS Number	114333-71-0;
PubChem CID	9841972;
ChemSpider	2343;
UNII	5DZZ1926YW;
ChEBI	CHEBI:131180;
ChEMBL	ChEMBL284782;
CompTox Dashboard (EPA)	DTXSID101126185 ;
Chemical and physical data
Formula	C19H22ClNO4
Molar mass	363.84 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H](CC1=CC=C(C=C1)OCC(=O)O)NC[C@@H](C2=CC(=CC=C2)Cl)O;
	InChI InChI=1S/C19H22ClNO4/c1-13(21-11-18(22)15-3-2-4-16(20)10-15)9-14-5-7-17(8-6-14)25-12-19(23)24/h2-8,10,13,18,21-22H,9,11-12H2,1H3,(H,23,24)/t13-,18+/m1/s1; Key:ZGGNJJJYUVRADP-ACJLOTCBSA-N;

BRL-37344 is a drug which acts as a selective agonist of the β₃ adrenergic receptor,^[1] which has been investigated for various biomedical research applications but never developed for clinical use.^[2]^[3]^[4]^[5]^[6]^[7]

References

^ Bond RA, Clarke DE (November 1988). "Agonist and antagonist characterization of a putative adrenoceptor with distinct pharmacological properties from the alpha- and beta-subtypes". British Journal of Pharmacology. 95 (3): 723–734. doi:10.1111/j.1476-5381.1988.tb11698.x. PMC 1854239. PMID 2905184.
^ Napp A, Brixius K, Pott C, Ziskoven C, Boelck B, Mehlhorn U, et al. (February 2009). "Effects of the beta3-adrenergic agonist BRL 37344 on endothelial nitric oxide synthase phosphorylation and force of contraction in human failing myocardium". Journal of Cardiac Failure. 15 (1): 57–67. doi:10.1016/j.cardfail.2008.08.006. PMID 19181295.
^ Afeli SA, Rovner ES, Petkov GV (September 2013). "BRL37344, a β3-adrenergic receptor agonist, decreases nerve-evoked contractions in human detrusor smooth muscle isolated strips: role of BK channels". Urology. 82 (3): 744.e1–744.e7. doi:10.1016/j.urology.2013.05.027. PMC 3758792. PMID 23890664.
^ Maryanovich M, Zahalka AH, Pierce H, Pinho S, Nakahara F, Asada N, et al. (June 2018). "Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche". Nature Medicine. 24 (6): 782–791. doi:10.1038/s41591-018-0030-x. PMC 6095812. PMID 29736022.
^ Xu Z, Wu J, Xin J, Feng Y, Hu G, Shen J, et al. (September 2018). "β₃-adrenergic receptor activation induces TGFβ1 expression in cardiomyocytes via the PKG/JNK/c-Jun pathway". Biochemical and Biophysical Research Communications. 503 (1): 146–151. doi:10.1016/j.bbrc.2018.05.200. PMID 29859189. S2CID 44151793.
^ Grzelka K, Gawlak M, Czarzasta K, Szulczyk P (April 2019). "Effects of β₃-adrenergic receptor stimulation on the resting holding current of medial prefrontal cortex pyramidal neurons in young rats". Neuroscience Letters. 698: 192–197. doi:10.1016/j.neulet.2019.01.022. PMID 30641111. S2CID 58668177.
^ Fellous TG, Redpath AN, Fleischer MM, Gandhi S, Hartner SE, Newton MD, et al. (2020). "Pharmacological tools to mobilise mesenchymal stromal cells into the blood promote bone formation after surgery". npj Regenerative Medicine. 5: 3. doi:10.1038/s41536-020-0088-1. PMC 7035363. PMID 32133156.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Bond RA, Clarke DE (November 1988). "Agonist and antagonist characterization of a putative adrenoceptor with distinct pharmacological properties from the alpha- and beta-subtypes". British Journal of Pharmacology. 95 (3): 723–734. doi:10.1111/j.1476-5381.1988.tb11698.x. PMC 1854239. PMID 2905184.

[2] Napp A, Brixius K, Pott C, Ziskoven C, Boelck B, Mehlhorn U, et al. (February 2009). "Effects of the beta3-adrenergic agonist BRL 37344 on endothelial nitric oxide synthase phosphorylation and force of contraction in human failing myocardium". Journal of Cardiac Failure. 15 (1): 57–67. doi:10.1016/j.cardfail.2008.08.006. PMID 19181295.

[3] Afeli SA, Rovner ES, Petkov GV (September 2013). "BRL37344, a β3-adrenergic receptor agonist, decreases nerve-evoked contractions in human detrusor smooth muscle isolated strips: role of BK channels". Urology. 82 (3): 744.e1–744.e7. doi:10.1016/j.urology.2013.05.027. PMC 3758792. PMID 23890664.

[4] Maryanovich M, Zahalka AH, Pierce H, Pinho S, Nakahara F, Asada N, et al. (June 2018). "Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche". Nature Medicine. 24 (6): 782–791. doi:10.1038/s41591-018-0030-x. PMC 6095812. PMID 29736022.

[5] Xu Z, Wu J, Xin J, Feng Y, Hu G, Shen J, et al. (September 2018). "β₃-adrenergic receptor activation induces TGFβ1 expression in cardiomyocytes via the PKG/JNK/c-Jun pathway". Biochemical and Biophysical Research Communications. 503 (1): 146–151. doi:10.1016/j.bbrc.2018.05.200. PMID 29859189. S2CID 44151793.

[6] Grzelka K, Gawlak M, Czarzasta K, Szulczyk P (April 2019). "Effects of β₃-adrenergic receptor stimulation on the resting holding current of medial prefrontal cortex pyramidal neurons in young rats". Neuroscience Letters. 698: 192–197. doi:10.1016/j.neulet.2019.01.022. PMID 30641111. S2CID 58668177.

[pmid32133156-7] Fellous TG, Redpath AN, Fleischer MM, Gandhi S, Hartner SE, Newton MD, et al. (2020). "Pharmacological tools to mobilise mesenchymal stromal cells into the blood promote bone formation after surgery". npj Regenerative Medicine. 5: 3. doi:10.1038/s41536-020-0088-1. PMC 7035363. PMID 32133156.

[1]

[2]

[3]

[4]

[5]

[6]

[7]